| Cat. No. |
Product Name |
Information |
| PC-42566 |
SCIO-469
p38α MAPK inhibitor
|
Talmapimod (SCIO469) is a potent, selective p38α MAPK inhibitor with IC50 of 9 nM. |
| PC-42512 |
SB 202190
|
SB 202190 (SB202190, SB-202190) is a potent inhibitor p38α and p38β with IC50 of 50 nM and 100 nM respectively. |
| PC-42526 |
VX-745
p38α MAPK inhibitor
|
Neflamapimod (VX-745) is a potent and selective p38α kinase inhibitor with IC50 of 9 nM. |
| PC-42520 |
Doramapimod
|
Doramapimod (BIRB-796) is a highly potent p38 MAPK inhibitor with Kd of 0.1 nM. |
| PC-22072 |
CHF6297
p38α/β inhibitor
|
CHF6297 (CHF-6297) is a potent and selective p38α/β MAPK inhibitor with IC50 of 0.14/0.2 nM, >1,000-fold selectivity against p38γ and p38δ. |
| PC-21600 |
BMS-582949
p38 MAPK inhibitor
|
BMS-582949 is a potent, selective and orally active p38α MAP kinase inhibitor with IC50 of 13 nM, exhibits significant inhibition of TNFα release in hPBMC with IC50 of 50 nM. |
| PC-21599 |
Dilmapimod
p38 MAPK inhibitor
|
SB-681323 is a potent and selective p38 MAPK inhibitor, potentially suppresses inflammation in chronic obstructive pulmonary disease. |
| PC-21598 |
PH797804
p38 MAPK inhibitor
|
PH-797804 is a potent, highly selective and ATP-competitive p38α/p38β MAPK inhibitor with IC50 of 2.3 nM (p38α). |
| PC-21017 |
NDPPC
p38⍺ MAPK inhibitor
|
NDPPC is a small molecule p38⍺ MAPK inhibitor, augments cardiomyocyte cell cycle response to cell cycle factors, CDK1, CDK4, cyclin B1, and cyclin D1 (4F). |
| PC-20954 |
NC-p38i NC-37
p38α inhibitor
|
Non-canonical p38α inhibitor NC-37 (NC-p38i NC-37) is a potent, highly selective, non-canonical inhibitor of p38α, inhibits TAB1-induced p38α autophosphorylation in vitro with IC50 of 0.27 uM. |
| PC-20953 |
NC-p38i NC-38
p38α inhibitor
|
Non-canonical p38α inhibitor NC-38 (NC-p38i NC-38) is a potent, highly selective, non-canonical inhibitor of p38α, inhibits TAB1-induced p38α autophosphorylation in vitro with IC50 of 0.27 uM. |
| PC-49694 |
VCP979
p38 MAPK inhibitor
|
VCP979 (VCP-979) is a novel selective small molecule p38 MAPK inhibitor with a significantly greater affinity for the active form of p38 MAPK, has significant anti-fibrotic effects in vitro and in vivo. |
